Redeye provides an update post Embracers Q4 2022/23 results. The report was softer than expected, while the guidance for FY2023/24e was lowered. As such, we revise our estimates and valuation accordingly.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/